Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Carotid Filtration During Endovascular Aortic Valve Implantation

This study has been completed.
Meditrial Europe Ltd.
Information provided by (Responsible Party):
Claret Medical Identifier:
First received: November 24, 2011
Last updated: December 2, 2011
Last verified: December 2011
This study was designed as a First In Man (FIM) trial to evaluate the feasibility and technical capability of the Claret CE Pro System in delivering two embolic filters to the brachiocephalic artery and the left common carotid artery during a Transcatheter aortic valve implantation (TAVI) procedure in order to protect the neurovasculature from debris liberated during the procedure.

Condition Intervention
Heart Diseases
Device: CE Pro System

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Supportive Care
Official Title: Carotid Filtration During Endovascular Aortic Valve Implantation

Further study details as provided by Claret Medical:

Primary Outcome Measures:
  • Primary endpoint is technical success of the CE Pro System to deliver, retrieve proximal & distal filters during an endovascular procedure such as Transcatheter aortic valve implantation (TAVI). [ Time Frame: From the CE Pro System Insertion Start Time to Final Retrieval Stop Time ]

    Technical success defined as, successful delivery & retrieval of the proximal & distal filters.

    The following Operator feedback was collected & used to evaluate the primary endpoint.

    Operators are asked to record, the indwelling time for the CE Pro System was used. Calculated as duration from the CE Pro System Insertion Start Time to Final Retrieval Stop Time.

    Operators are asked to rate the CE Pro Systems performance based on a scale of 1 to 5, with 5 being the highest rating.

Secondary Outcome Measures:
  • Transient Ischemia Attack (TIA) Rates [ Time Frame: 30 day follow up ]
    The secondary endpoints for this trial are safety endpoints and are presented as adverse events.

Enrollment: 38
Study Start Date: February 2010
Study Completion Date: May 2011
Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
Intervention Details:
    Device: CE Pro System
    The CE Pro System consists of a delivery catheter with an integrated proximal filter intended to be deployed in the brachiocephalic artery. In addition, the device has an articulating distal tip and a through lumen to allow a commercial intravascular filter to be back-loaded into the CE Pro System and be deployed into and retrieved from the left carotid artery.
    Other Names:
    • Gen 2.0
    • Gen 2.1
    • Gen 2.2
Detailed Description:

Transcatheter aortic valve implantation (TAVI) is a recently developed procedure whereby a prosthetic aortic valve is implanted percutaneously, and the procedure has demonstrated promising results in high risk surgical populations.

TAVI currently requires the use of large bore (18-26F) catheter delivery systems that are often difficult to deliver to over the aortic arch to the aortic annulus. Available data indicate that TAVI is associated with a 4-12% procedural stroke rate and approximately 10% procedural mortality. It has been suggested that these strokes are most likely caused by the liberation of embolic debris either when the TAVI delivery catheter is advanced over the aortic arch or during the actual valve deployment. Given this situation, the availability of devices able to protect both hemispheres of the brain from potentially embolic debris during the TAVI procedure is an emerging clinical need.

Claret Medical has developed a technology to provide protection to the neurovascular system during TAVI and other valve repair procedures.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject must be scheduled to undergo an endovascular aortic valve prosthesis implant procedure with the femoral artery as the intended access site for the valve delivery system.
  • Female subjects of child bearing potential must have a negative pregnancy test within 48 hours prior to the study procedure.
  • Subject's left carotid artery and innominate artery diameters must be compatible with the Claret CE Pro System sizes available for the procedure (refer to package labeling for appropriate sizing information).
  • Subject must have been informed of the nature of the study, agree to its provisions, and provide written informed consent.

Exclusion Criteria:

  • Subject requires an emergent procedure.
  • Subject has carotid artery stenosis >70% in either carotid artery.
  • Subject innominate or left carotid artery reveals significant stenosis, ectasia, dissection or aneurysm at the ostium or within 3 cm of the ostium.
  • Subject has allergy to materials from which the device is constructed (Nitinol, fluorinated ethylene-propylene, polyamide, polyimide, platinum, iridium, stainless steel, cyanoacrylate adhesives, polycarbonate, polyethylene, polyester, polyurethane, PTFE [poly-tetrafluoroethylene], polydimethylsiloxane [lubricant coating], silicone, polyetheretherketone, tin-silver [solder] or acrylated urethane adhesives)
  • Subject has a history of bleeding diatheses or coagulopathy or will refuse blood transfusion in cases of emergency.
  • Subject has renal insufficiency, defined as a creatinine level > 2.5 mg/dl at the time of treatment, unless subject is on chronic hemodialysis.
  • Subject has hyperthyroidism.
  • Subject suffered recent (within the past 3 months) stroke with permanent deficit.
  • Subject suffered recent (within the past 6 months) significant gastrointestinal (GI) bleed.
  • Subject is involved in another clinical study or has other medical illnesses that may cause the subject to be non-compliant with the protocol or confound the data interpretation.
  • Subject history of intolerance, allergic reaction or contraindication to any of the study medications, including heparin, aspirin, Clopidogrel, or a sensitivity to contrast media or anesthesia which cannot be adequately pre-treated.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01484249

Sponsors and Collaborators
Claret Medical
Meditrial Europe Ltd.
Principal Investigator: Eberhard Grube, MD, Ph D Professor of Medicine, Medizinishce Klinik und Poliklinik II, Universitätsklinikum Bonn
  More Information

Responsible Party: Claret Medical Identifier: NCT01484249     History of Changes
Other Study ID Numbers: CMP 001b
Study First Received: November 24, 2011
Last Updated: December 2, 2011

Keywords provided by Claret Medical:

Additional relevant MeSH terms:
Heart Diseases
Cardiovascular Diseases processed this record on April 28, 2017